Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Hosted on MSN
Vertex sees 14.6% revenue growth for 2025 with focus on new AI and e-invoicing investments
CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...
Schwab provided guidance for Q3 2025, expecting revenues of $190 million to $193 million and adjusted EBITDA of $38 million to $40 million. For the full year, the company now expects revenues of $750 ...
For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback